Prolacta Bioscience, a Monrovia, Calif.-based life science company that offers human milk fortifier (HMF) made from 100% human breast milk for critically ill, premature infants, has raised an undisclosed sum of Series D funding from Health Evolution Partners (HEP).
The capital will be used to fund a second facility and to support growth of Prolacta’s sales organization.
The company’s primary product is Prolact+ H2MF®, a human milk fortifier made exclusively from human milk for extremely premature infants in neonatal intensive care units (NICU).
The product is prescribed by neonatologists for infants weighing two pounds 12 ounces (1250 grams) or less at birth. It is concentrated breast milk that is added to the mother’s breast milk or to donor milk (if a mother’s own milk is unavailable), in order to meet the precise protein and caloric needs of the preemie. Prolact+ H2MF can only be administered in a hospital setting and cannot be purchased directly by consumers.
In conjunction with the funding, Ned Brown, Investment Partner at Health Evolution Partners, and Joshua Saipe, Vice President of Health Evolution Partners’ Growth Fund, joined Prolacta’s board of directors.
The company is led by CEO Scott Elster.